Results 161 to 170 of about 5,574 (244)

A Phase III Randomized Trial Comparing Efficacy, Safety, and Immunogenicity of ZRC-3285 vs. Eylea^® in Patients with Wet Age-Related Macular Degeneration. [PDF]

Ophthalmol Ther
Bansal M, Singh P, Mehta RK, Laul RS, Rana P, Shah U, Vohra R, Desai S, Bhomaj S, Patwardhan S, Manoher JM, Sapar A, Parwal S, Amabde AK, Shroff R, Natesh S, Biswas RK, D LR, Sinha BP, C K M, Patel E, Kamble A, Bhende P, Patil S, Shah A, Narula R, Kumari B, Bathula L, Kirtane S, Darji B, Doshi M, Parmar D.   +31 more
europepmc   +1 more source

Efficacy and safety of denosumab biosimilars in the treatment of postmenopausal osteoporosis: A systematic review of randomized clinical trials. [PDF]

Clin Exp Med
Shakibaei F, Malekshahi S, Heidari N, Heidari A.   +3 more
europepmc   +1 more source

Will the emerging private-label market access channel help or hinder biosimilar market access? [PDF]

J Manag Care Spec Pharm
Mehr SR.
europepmc   +1 more source

Antitrust and the Biopharmaceutical Industry: Lessons from Hatch-Waxman and an Early Evaluation of the Biologics Price Competition and Innovation Act of 2009 [PDF]

, 2010
Seamon, Matthew J
core   +1 more source

Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease. [PDF]

World J Gastroenterol
Kritzinger J, Candel I, Kotrri G, Nadeem H, Afif W, Bitton A, Wild G, Bessissow T, Lakatos PL.   +8 more
europepmc   +1 more source

HASH(0x563d440b87b0) [PDF]

, 2007
Groth, S.
core  

How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009–2013 [PDF]

, 2015

core   +1 more source

Characterization of a Long-Acting Anti-Human MASP-2 Antibody for the Treatment of Complement-Related Diseases. [PDF]

J Inflamm Res
Han X, Yang C, Wang Z, Fan K, Liu K, Ye H, Zhang W, Zhang J, Hu X, Lin H, Liao C.   +10 more
europepmc   +1 more source

Efficacy & safety of adalimumab biosimilar in axial spondyloarthritis: A retrospective study from a tertiary care centre in South India. [PDF]

Indian J Med Res
Gopalan A, Gavali M, Yerram K.
europepmc   +1 more source

Barriers to Biosimilar Approval: Creating Clarity Through the Publication of Product-Class Specific Guidances [PDF]

, 2016
McEnrue, Martin
core